Secukinumab (Cosentyx®) accepted for use within NHS Scotland for treatment of active non-radiographic axial spondyloarthritis

Approval is based on a randomised phase III study, in which secukinumab, compared with placebo, significantly improved symptoms in adults with active non-radiographic axial spondyloarthritis.

Scottish Medicines Consortium